Property:Inclusion criteria
This is a property of type Text.
M
Muecke et al. (2014): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization +
NA +
N
Najafizade et al. (2013): Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial +
Head and neck cancers who were on schedule for radiotherapy with at least 2000 Gy ot >30% of oral cavity, with or without chemotherapy +
Nasser et al. (2017): Vitamin D ointment for prevention of radiation dermatitis in breast cancer patients +
Women aged 18 to 75 years with a confirmed histological diagnosis of localized breast cancer, after breast lumpectomy, and scheduled to receive adjuvant radiotherapy +
Newling et al. (1995): Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group +
Patients with histologically proven Ta/T1, NO or NX, MO transitional cell carcinoma ofthe bladder completely removed by transurethral resection or fulguration before the start of oral therapy; no previous therapy other than transurethral resection or fulguration; estimated survival of more than 3 years +
Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial +
Pathologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the colon or rectum with measurable disease per version 1.1 of the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines; patients were eligible if they received prior neoadjuvant or adjuvant chemotherapy or chemoradiation as long as the last dose of treatment was more than 12 months prior to cancer recurrence; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, normal baseline organ function, and no evidence of hypercalcemia or conditions predisposing to hypercalcemia (ie, hyperparathyroidism). +
Nguyen et al. (2012): Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities +
Biopsy-proved prostate cancer; received no other therapy for their prostate cancer; current PSA less than 50 ng/mL; older than 18 years; no history of chemotherapy and/or radiation for any malignancy in the previous 5 years; good performance status; normal renal function (creatinine ≤ institutional upper limits of normal); normal hepatic function (total bilirubin, aspartate aminotransferase (AST; SGOT)/alanine aminotransferase (ALT; SGPT) ≤ institutional upper limits of normal) +
Niravath et al. (2019): Randomized controlled trial of high‐dose versus standard‐dose vitamin D3 for prevention of aromatase inhibitor‐induced arthralgia +
≥ 21 years old, with stage I-III hormone receptor-positive breast cancer, who were beginning adjuvant aromatase inhibitor therapy;
post-menopausal, defined as any of the following: age ≥ 60 years old; history of bilateral oophorectomy; or serum estradiol and FSH concentrations in the post-menopausal range, along with either amenorrhea for 12 months or previous hysterectomy; if the patient was < 60 years old at the time of study enrollment and had completed chemo- therapy, post-menopausal status had to have been confirmed prior to chemotherapy +
O
Okabayashi et al. (2020): L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients +
Preoperative contrast-enhanced computed tomography was available within 30 days of the scheduled surgery.
Criteria for hepatectomy included:
* Absence or controllability of ascites.
* Serum total bilirubin level ≤2 mg/dL (no patients required diuretics for ascites) +
Olsen et al. (2001): The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy +
Cancer patients undergoing radiotherapy +
Ota et al. (2014): The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study +
Histologically confirmed colorectal cancer (adenocarcinoma); histological stage III colon cancer or rectosigmoid cancer resected with D2 or more lymph node dissection; age 20-80 years old; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; no prior chemotherapy or radiotherapy for target disease; oral intake is possible; preservation of primary organ function (white blood cell count ≥3,000 /mm3 and >12,000 /mm3, neutrophil count ≥1,500 /mm3, haemoglobin ≥9.0 g/dL, platelet count ≥100,000 /mm3; serum creatinine <1.5 mg/dL, serum total bilirubin <1.5 mg/dL, aspartate aminotransferase (ALT) <100 IU/L); able to start protocol treatment within 8 weeks of surgical procedure +
P
Pace et al. (2003): Neuroprotective Effect of Vitamin E Supplementation in Patient Treated With Cisplatin Chemotherapy +
Patients with solid malignancies and a Karnofsky Performance Status between 70 to 100 +
Patients with solid malignancies and Karnofsky Performance Status 70–100 +
Panahi et al. (2012): Effect of Ginger on Acute and Delayed Chemotherapy-Induced Nausea and Vomiting: A Pilot, Randomized, Open-Label Clinical Trial +
Women who had cancer (mainly new cases of advanced breast cancer diagnosed by the oncologist and thus undergoing their first experience of chemotherapy) who were initially assigned to the components of TEC regimen, including docetaxel, epirubicin, and cyclophosphamide +
Paur et al. (2017): Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA +
Patients diagnosed with non-metastatic prostate cancer (N0 and M0 as confirmed by negative chest X-ray, bone scintigraphy and pelvic MRI or CT); scheduled for either radical prostatectomy or high-dose radiotherapy consisting of a combination of high-dose rate brachytherapy and pelvic external beam radiotherapy +
Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial +
Adult patients with active cancer and chronic pain (moderate or severe despite a stable opioid regimen that could not be made more effective by further opioid dose titration); stable, average pain: NRS: ≥4≤ 8 (no change in 3 days > 2 points) +
Puataweepong et. al (2009): The efficacy of oral Aloe vera juice for radiation induced mucositis in head and neck cancer patients: a double-blind placebo-controlled study +
Stage II-IVMO cancer of the head and neck; radiotherapy in adjuvant or definitive setting; Karnofsky performance > 70. +
Patients with high-grade gliomas (anaplastic astrocytoma or glioblastoma multiforme) +
R
Raei et al. (2013): Effect of herbal therapy to intensity chemotherapy-induced nausea and vomiting in cancer patients +
Age over 18, having the experience of chemotherapy with nausea and vomiting, having at least two chemotherapy episodes. Consists of 50-100 mg Cisplatin, with or without other chemotherapy agents with similar amount and prescription in two chemotherapy cycles without having any plans for radiotherapy among cycles; presence in ward for 24 hours ( in order to investigate the PRN; having no nausea and vomiting experiences for some reasons except for chemotherapy; lack of receiving PRN in 24 past hours; lack of treatment with corticosteroid drugs during considered cycles; lack of afflictions to hepatitis, digestion system blockage, brain malignancy and cerebral metastasis and clotting disorder on the basis of recorded information in files; lack of using the anti-clot drug +
Rao et al. (2014): The Indian Spice Turmeric Delays and Mitigates Radiation-Induced Oral Mucositis in Patients Undergoing Treatment for Head and Neck Cancer: An Investigational Study +
NI +
Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial +
From 18 to 68 years, in complete remission of the disease and bone marrow (NCCN guidelines), with optimal kidney and liver functions +